Filing Flows › Citius Pharmaceuticals (CTXR) › Q2 FY26
Citius Pharmaceuticals (CTXR) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed May 15, 2026
Citius Pharmaceuticals (CTXR) reported revenue of $1.7M for the second quarter fiscal 2026 (Q2 FY26) and -58% from the quarter before.
Citius Pharmaceuticals, Q2 FY26: revenue $1.7M, net loss $28.1M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -58% | — |
| Operating profit | −$32.2M | — | — |
| Net earnings | −$28.1M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $1.7M in Q2 FY26, down 58% from the previous quarter.
Gross margin was 80.3%. Operating costs exceeded revenue by $32.2M, an operating margin of -1931.0%. The quarter ended with a net loss of $28.1M, wider than the previous quarter's $9.4M loss. Minority interests bore $6.9M of it: to shareholders the quarter was a loss of $21.2M.
Operating cash flow was −$1.3M. Non-cash charges added back $3.8M of share-based compensation. Working capital and other items added $23.0M.
Questions
What was Citius Pharmaceuticals' revenue in the second quarter fiscal 2026?
Citius Pharmaceuticals (CTXR) reported revenue of $1.7M for the second quarter fiscal 2026 (Q2 FY26) and -58% from the quarter before.